A randomised phase 1 clinical trial conducted by scientists and doctors from Shanghai and Guangzhou has achieved encouraging results in the treatment of Type 1 diabetes using stem cells extracted from the mouth’s gum tissue.
More than half of those who received the treatment showed varying degrees of improvement, while one subject was able to discontinue exogenous insulin therapy completely, the researchers said.
Results of the study, which tested a therapy based on gingival mesenchymal stem cells (GMSC), appeared on September 30 in the medical journal Signal Transduction and Targeted Therapy.